logo-loader
ASX:IMU

Imugene Ltd

Receive alerts
Market:
ASX
Market Cap:
$79.42 m
Price
$0.02
Change
0.00%
52 weeks high
0.03
52 weeks low
0.01

Viewing results 1-25 of 74

Health

Imugene to acquire exclusive licence for potentially transformational oncolytic virus technology

A phase-one clinical trial in 30 patients with advanced tumours is expected to start in 2020 across a number of US cancer centres....

on 15/7/19
Health

Imugene reveals new clinical data for HER-Vaxx vaccine showing cancer-fighting response

HER-Vaxx is a B-cell peptide cancer vaccine designed to treat tumours in gastric, breast, ovarian, lung and pancreatic cancers....

on 8/7/19
Health

Imugene presents new HER-Vaxx cancer vaccine results

Results were presented at the ASCO annual meeting in Chicago, which attracts over 40,000 cancer specialists....

on 4/6/19
Health

Imugene appoints venture capital executive to board

The company finished the March quarter with $21 million in the bank....

on 20/5/19
Health

Imugene to present new data from HER-Vaxx cancer vaccine phase 1b trial

Imugene’s HER-Vaxx is a B-cell peptide cancer vaccine designed to treat tumours that over-express the HER-2/neu receptor....

on 29/4/19
Health

Imugene appoints global pharmaceutical executive to its board

Dr. Lesley Russell brings extensive pharmaceutical experience to the board including a number of cancer therapy collaborations with Teva Pharmaceuticals....

on 23/4/19
Health

Imugene well-funded to progress clinical milestones

The company is currently fully funded in supporting all clinical research programs....

on 16/4/19
Health

Imugene presents positive new data validating its human cancer vaccine KEY-Vaxx

The Medical University Vienna and Imugene are working to develop mimotope based cancer vaccines....

on 3/4/19
Health

Imugene reveals new data on cancer vaccine programs

Data shows combining KEY-Vaxx and B-Vaxx is more effective than KEY-Vaxx alone....

on 2/4/19
Health

Imugene gets development roadmap for cancer vaccine from FDA meeting

The company had a pre-investigational new drug (IND) meeting with the FDA last month....

on 20/3/19
Health

Imugene doses milestone first patient for cancer vaccine trial

The first patient was dosed in the Eastern European country of Moldova....

on 14/3/19
Health

Imugene to make further cancer vaccine research presentations at AACR annual meeting

The AACR annual meeting will be held in Atlanta Georgia, between March 29 and April 3....

on 4/3/19
Health

Imugene to present cancer vaccine research at AACR annual meeting

The company has multiple B-cell vaccine candidates aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies....

on 28/2/19
Health

Imugene has cancer vaccine trial data published in prestigious medical journal

Imugene is an Australian biotechnology company developing cancer immunotherapies, with operations in the U.S. and in Europe....

on 26/2/19
Health

Imugene targets defender B-cells with cancer vaccines HER-Vaxx and B-Vaxx

The company’s B-cell peptide cancer vaccines have shown promise in pre-clinical and early-stage study....

on 13/2/19
Health

Imugene begins manufacture of its innovative cancer vaccine for trials

KEY-Vaxx has shown potential in preclinical studies, outperforming an industry-standard antibody....

on 24/9/18
Health

Imugene signs exclusive, world-wide licence for cancer vaccine

Imugene is a clinical stage immuno-oncology company....

on 7/6/18
Health

Imugene pounces on material acquisition

Imugene is an immuno-oncology company focused on gastric cancer....

on 5/6/18
Health

Imugene’s shares surge higher following early promise in gastric cancer trial

The company is well funded with a cash balance of circa $12 million as at 31 December 2017....

on 7/2/18